AvramMRoggHKordaA, et al. (2021). Bridging the gap? Altered thalamocortical connectivity in psychotic and psychedelic states. Front Psychiatry12: 706017.
2.
BraillonANaudetF. (2023) Marketing pitches of ‘magic mushrooms’ and ‘psychedelics’ mask that psychotomimetics use exposes those vulnerable to serious adverse effects. J Psychopharmacol37: 749–751.
3.
CarbonaroTMBradstreetMPBarrettFS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol6: 1268–1278.
4.
Carhart-HarrisRLGoodwinGM (2017) The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology42: 2105–2113.
5.
HuxleyA (1961) US State department-sponsored speech to the Tavistock Group. California Medical School.
6.
NooraniT (2020) Making psychedelics into medicines: The politics and paradoxes of medicalization. J Psychedelic Stud4: 34–39.
7.
OnaGSDos SantosRGHallakJEC, et al. (2020). Polypharmacology or “pharmacological promiscuity” in psychedelic research: What are we missing?ACS Chem Neurosci11: 3191–3193.
8.
SapienzaJBosiaMSpangaroM, et al. (2023) Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes. Mol Psychiatry28: 59–67.
9.
WießnerIFalchiMPalhano-FontesF, et al. (2021) LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med13: 1–15.
